Drugs / OC-01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05136924 | Dec 2021 → Jun 2022 | dry eye syndrome | Vance Thompson Vision - MT | Unknown | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT05161208 | Dec 2021 → Jul 2022 | dry eye syndrome | Center for Ophthalmic and Vision Research, LLC | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04957758 Comparator | Jun 2021 → Jan 2023 | neurotrophic keratopathy | Oyster Point Pharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03873246 Comparator | Feb 2019 → Jan 2020 | dry eye syndrome | Oyster Point Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OC-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05136924 ↗ |
| Known as | varenicline | “OC-01 (varenicline) nasal spray 1.2 mg/ml” NCT04957758 ↗1“OC-01 (varenicline 0.6mg/ml) Nasal Spray” NCT05161208 ↗ |
| Action | Activate | “nicotinic acetylcholine receptor agonist” PMID 34920097 ↗ Dec 2021 |
| Modality | Small molecule | “OC-01 (varenicline solution) is a small-molecule nicotinic acetylcholine receptor agonist” PMID 34920097 ↗ Dec 2021 |
| Route | Intranasal | “administered twice daily via intranasal spray” PMID 34920097 ↗ Dec 2021 |